IMCC logo

IM CANNABIS CORP

IMCCNASDAQ
πŸ† #4182 by market capUS Equity
$0.13β–² $0.00 (+1.77%)
πŸŒ™ After hours$0.13β–Ό 1.06%Regular close Β· extended-hours price shown
1hβ€”
24hβ–² 1.8%
7dβ–² 6.2%
14dβ–² 27.1%
30dβ–Ό 11.9%
1yβ–Ό 95.2%
🏦Market Cap
$408,205
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.3%
Slowing
πŸ“ŠGross Margin
27.3%
Moderate
πŸ’΅FCF Margin
15.8%
Healthy
βš–οΈP/S Ratio
0.7x
Cheap
Otter Score
59
Weak

Trading Snapshot

Day Range
$0.13 – $0.13
52-Week Range
$0.10 – $3.13
Volume
$1.88B
Avg Volume
$1.49B
Shares Outstanding
3.1M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$55M
Last Q Revenue
$9M
P/E Ratio
-1062.5
P/S Ratio
0.7x
EPS (TTM)
$-0.04
Dividend Yield
0.00%

Why Investors Own IMCC

  • βœ“High-growth profile β€” revenue up +1.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$55Mβ–² +0.2% YoY
Gross Margin (TTM)
71.5%β–² +2.0% YoY
Operating Income (TTM)
$15Mβ–² +0.2% YoY
Free Cash Flow (TTM)
$10Mβ–² +0.2% YoY

About IM CANNABIS CORP

IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods throughout international markets such as Israel, Germany, and Canada. The company offers a range of cannabis products, including flowers and specifically formulated cannabis extracts, marketed under its IMC brand. Furthermore, it supplies dried flower, pre-rolled products, and compressed hashish via its WAGNERS and Highland Grow labels. IM Cannabis Corp. serves a broad customer base, addressing the needs of both medical patients and adult recreational consumers. Its corporate headquarters are located in Tel Aviv-Yafo, Israel.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
59/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2023

Latest News & Updates